Last reviewed · How we verify
Neupro®
Neupro is a dopamine agonist that stimulates dopamine receptors in the brain to restore dopamine signaling in patients with Parkinson's disease and restless legs syndrome.
Neupro is a dopamine agonist that stimulates dopamine receptors in the brain to restore dopamine signaling in patients with Parkinson's disease and restless legs syndrome. Used for Parkinson's disease (early-stage and advanced), Restless legs syndrome (moderate to severe).
At a glance
| Generic name | Neupro® |
|---|---|
| Also known as | Rotigotine |
| Sponsor | UCB Pharma |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors (D1, D2, D3, D4, D5) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Neupro (rotigotine) is a non-ergot dopamine agonist that works by binding to dopamine receptors (D1-D5) in the central nervous system. In Parkinson's disease, it compensates for the loss of dopamine-producing neurons by directly activating dopamine receptors, thereby improving motor symptoms such as tremor, rigidity, and bradykinesia. In restless legs syndrome, it reduces the abnormal sensations and involuntary movements by restoring dopaminergic tone in the spinal cord and brain regions involved in motor control.
Approved indications
- Parkinson's disease (early-stage and advanced)
- Restless legs syndrome (moderate to severe)
Common side effects
- Application site reactions (erythema, pruritus)
- Nausea
- Dizziness
- Somnolence
- Headache
- Vomiting
- Orthostatic hypotension
Key clinical trials
- Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder (PHASE2)
- Adhesion and Safety of Rotigexole Compared to Neupro® (NA)
- Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (PHASE4)
- Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease (PHASE2)
- A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro (PHASE1)
- An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine. (PHASE1)
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers (PHASE1)
- Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neupro® CI brief — competitive landscape report
- Neupro® updates RSS · CI watch RSS
- UCB Pharma portfolio CI